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Abstract
Group A Rotaviruses (RVA) are double stranded RNA viruses that are a significant cause of acute 
pediatric gastroenteritis. Beginning in 2006 and 2008, respectively, two vaccines, Rotarix™ and 
RotaTeq®, have been approved for use in the USA for prevention of RVA disease. The effects of 
possible vaccine pressure on currently circulating strains in the USA and their genome 
constellations are still under investigation. In this study we report 33 complete RVA genomes 
(ORF regions) collected in multiple cities across USA during 2006 – 2009, including 8 collected 
from children with verified receipt of 3 doses of rotavirus vaccine. The strains included 16 
G1P[8], 10 G3P[8], and 7 G9P[8]. All 33 strains had a Wa like backbone with the consensus 
genotype constellation of G(1/3/9)-P[8]-I1-R1-C1-M1-A1-N1-T1-E1-H1. From maximum 
likelihood based phylogenetic analyses, we identified 3 to7 allelic constellations grouped mostly 
by respective G types, suggesting a possible allelic segregation based on the VP7 gene of RVA 
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primarily for the G3 and G9 strains. The vaccine failure strains showed similar grouping for all 
genes in G9 strains and most genes of G3 strains suggesting that these constellations were 
necessary to evade vaccine-derived immune protection. Substitutions in the antigenic region of 
VP7 and VP4 genes were also observed for the vaccine failure strains which could possibly 
explain how these strains escape vaccine induced immune response. This study helps elucidate 
how RVA strains are currently evolving in the population post vaccine introduction and supports 
the need for continued RVA surveillance.
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1. Introduction
Group A Rotaviruses (RVA) are the major cause of acute gastroenteritis in children under 5 
years of age and the leading cause of gastroenteritis related deaths (~450,000) in developing 
countries every year (Estes and Kapikian, 2007; Parashar et al., 2009; Tate et al., 2012). In 
industrialized countries, RVA associated mortality is minimal yet the financial cost of 
treatment associated with disease burden is enormous (Payne et al., 2011). The RVA 
genome is composed of 11 double-stranded RNA (dsRNA) segments which code for 11or 
12 proteins in total, six structural proteins VP1-VP4, VP6 and VP7, and five or six 
nonstructural proteins NSP1-NSP5/6 (Estes and Kapikian, 2007). The VP7 and VP4 proteins 
form the outer layer of the viral capsid and have been historically used to classify RVA 
serotypes and genotypes into respective G and P types (Estes and Kapikian, 2007). These 
proteins have been extensively studied and a number of antigenic epitopes have been 
characterized. An extended classification system based on all 11 gene segments has been 
introduced by the Rotavirus Classification Working Group (RCWG) (Matthijnssens et al., 
2008b) and this classification system designates genotypes in the format Gx-P[x]-Ix-Rx-Cx-
Mx-Ax-Nx-Tx-Ex-Hx for the genes VP7, VP4, VP6, VP1-3, NSP1-5 respectively. Presently 
there are at least 27 G, 37 P, 16 I, 9 R, 9 C, 8 M, 16 A, 9 N, 12 T, 14 E, and 11 H types 
(Matthijnssens et al., 2011; Trojnar et al., 2013). The most common genogroup 
constellations worldwide based on the new classification are Wa like Genogroup 1 (Gx-
P[x]-I1-R1-C1-M1-A1-N1-T1-E1-H1) and DS-1 like Genogroup 2 (Gx-P[x]-I2-R2-C2-M2-
A2-N2-T2-E2-H2) (Matthijnssens et al., 2008b; Matthijnssens et al., 2012a). The genotype 
classification for an unknown strain is based on sequence identity cutoffs established by the 
RCWG and is currently implemented in the RotaC webserver (Maes et al., 2009).
In humans, the most common RVA G/P genotypes worldwide are G1P[8], G2P[4], G3P[8], 
G4P[8], and G9P[8] (Banyai et al., 2012; Gentsch et al., 2005). Two vaccines RotaTeq® 
(Merck) and Rotarix™ (GlaxoSmithKline) were introduced in the U.S. in 2006 and 2008, 
respectively (Cortese et al., 2009). RotaTeq® is a pentavalent human bovine reassortant 
vaccine which contains four G types (G1, G2, G3 and G4, VP7 gene) along with the P[8] 
VP4 type on a bovine WC3 (G6P[5]) backbone (Matthijnssens et al., 2010b). On the other 
hand, Rotarix™ is a human RVA derived G1P[8] strain (Ward, 2009). These vaccines have 
shown high efficacy in reducing the RVA burden in developed countries after their 
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introduction in various immunization programs (Gray, 2011). Unfortunately the same 
vaccines have much lower efficacy in some developing countries and this has caused some 
concern (Armah et al., 2010; Phua et al., 2009; Zaman et al., 2010). In addition it has been 
proposed that RVA vaccination in several countries may have driven the selection of new 
predominant genotypes through immune pressure (Carvalho-Costa et al., 2009; Hull et al., 
2011; Matthijnssens et al., 2012b; Zeller et al., 2010) though current evidence remains 
inconclusive. Globally, multiple surveillance networks have been established to study RVA 
prevalence in various countries (Carvalho-Costa et al., 2011; Hull et al., 2011; Iturriza-
Gomara et al., 2009; Kirkwood et al., 2010; Payne et al., 2008). In United States the two 
main RVA surveillance networks, National Rotavirus Strain Surveillance System (NRSSS) 
and the New Vaccine Surveillance Network (NVSN) have been established to monitor RVA 
strain prevalence in multiple parts of the country (Hull et al., 2011; Payne et al., 2008).
RVA genomes show high genomic diversity similar to other known RNA viruses. The 
diversity is generated by point mutations, reassortment, rearrangement and recombination 
events (Estes, 2007; Kirkwood et al., 2010). The proteins of RVA are known to evolve at 
substantially different rates with VP1 and VP2 being highly conserved whereas NSP1 is 
known to be highly divergent (Matthijnssens et al., 2008a). A recent study measured 
evolutionary rates of all 11 gene segments for the SA11-H96 strain and found nearly a 100 
fold difference in evolutionary substitution rates among the 11 gene segments (Mlera et al., 
2013). The evolutionary rates for the VP7 gene of G9 and G12 strains have also been 
calculated by Mathijnnesens et al to be 1.87 × 10−3 and 1.66 × 10−3 substitutions/site/year 
respectively (Matthijnssens et al., 2010a). Reassortment occurs when gene segments are 
exchanged between two different strains of RVA during a co-infection event. Multiple 
reassortments have been documented between two genogroups and also between different 
host species, albeit at a lower frequency (Varghese et al., 2004). Animal-to-human cross-
transmission and reassortment events between human and animal strains have been 
suggested as one of the possible reasons for the low vaccine efficacy in developing countries 
(Martella et al., 2010; Palombo, 2002). Reassortment has also been recently reported 
between sub-genotypic clusters (Maunula and Von Bonsdorff, 2002; McDonald et al., 
2012). Rearrangements events, although infrequent, have been observed in the NSP1 and 
NSP3 genes of cell culture passaged strains (Kojima et al., 2000). The short 
electropherotype of DS-1 like RVA strains is the result of naturally-occurring duplication 
and insertion events in the NSP5 genes (Giambiagi et al., 1994; Gonzalez et al., 1989). 
Intragenic recombination events are extremely rare and only a few cases have been reported 
in the VP7 and NSP2 genes (Donker et al., 2011; Phan et al., 2007). There is one report of 
intergenic recombination in the VP7 gene (Martinez-Laso et al., 2009).
In this study we sequenced complete open reading frames (ORFs) for 33 genogroup 1 strains 
(16 G1P[8], 10 G3P[8], and 7 G9P[8]) collected from multiple cities across the United 
States. Maximum likelihood based phylogenetic analysis along with other sequence analysis 
tools helped identify multiple sub-genotype allelic constellations recently circulating in 
USA. These sub allelic constellations may enhance our understanding of RVA evolution 
under vaccine pressure and help identify possible mechanisms of immune escape which 
result in RVA gastroenteritis in vaccinated individuals.
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2. Materials and Methods
2.1 Surveillance Testing and Genotyping
Fecal specimens were collected from children with acute gastroenteritis from 12 sites in the 
United States during the 2006-2007, 2007-2008, and 2008-2009 RVA seasons. All samples 
were tested by enzyme immunoassay (EIA) using the Premier® Rotaclone® Rotavirus 
Detection Kit (Meridian Diagnostics Inc., Cincinnati, OH). At the Centers for Disease 
Control and Prevention, (CDC), RVA dsRNA was extracted and VP7 and VP4 genotyping 
was carried out using a two-step amplification method as described previously (Hull et al., 
2011).
2.2 Sample Selection
A total of 33 samples were selected for genomic characterization of which 25 were from the 
NRSSS surveillance network and 8 from the NVSN. The NRSSS samples were selected 
based upon previous EIA and VP4/VP7 genotyping results and were collected from sites in 
Boston MA (1 sample), Chicago IL (1) Orlando FL (1), Fort Worth TX (6), Indianapolis IN 
(2), Long Beach CA (3), Omaha NE (3), San Francisco CA (1), and Seattle WA (7) whereas 
the NVSN samples were from study sites in Cincinnati OH (1), Nashville TN (1), and 
Rochester NY (6). Vaccination histories were available only for the children enrolled at 
NVSN sites. All 8 samples collected at NVSN sites were from children that received 3 doses 
of RotaTeq® vaccine.
2.3 Sanger Sequencing
Total RNA was extracted from 33 samples using MagNA Pure Compact extraction system 
with the RNA Isolation kit (Roche Applied Science, Indianapolis IN) and were sent to J. 
Craig Venter Institute for high-throughput Sanger sequencing. Oligonucleotide primers were 
designed using an automated primer design tool [PMID 18405373, 23131097]. Primers, 
with M13 tags added, were designed at intervals along both the sense and antisense strands, 
and provided amplicon coverage of at least 4-fold (see supplementary material). RT-PCRs 
were performed with 1 ng of RNA using OneStep RT-PCR kits (Qiagen, Valencia, CA) 
according to manufacturer's instructions with minor modifications: 1) reactions were scaled 
down to 1/5 the recommended volumes; 2) the RNA templates were denatured at 95°C for 5 
min; and 3) 1.6 U RNase Out (Invitrogen, Carlsbad, CA) was used. The RT-PCR products 
were sequenced with an ABI Prism BigDye v3.1 terminator cycle sequencing kit (Applied 
Biosystems, Carlsbad, CA). Raw sequence traces were trimmed to remove any primer-
derived sequence as well as low quality sequence, and gene sequences were assembled using 
Minimus, part of the open-source AMOS project [The AMOS project. http://
amos.sourceforge.net]. The gene sequences were then manually edited using ClOE (Closure 
Editor; JCVI) and ambiguous regions were resolved by additional sequencing when 
necessary.
2.4 Whole Genome Phylogenetic Analysis
Genotypes for each gene segment were determined using RotaC v2.0 webserver (Maes et 
al., 2009). For each gene, multiple alignments were made using the MUSCLE algorithm 
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implemented in MEGA 5.1 (Tamura et al., 2011). Maximum likelihood trees were 
constructed for each gene in PhyML 3.0 using the optimal model for each alignment as 
identified by jModeltest 2 and approximate Likelihood Ratio Test (aLRT) statistics 
computed for branch support (Anisimova and Gascuel, 2006; Darriba et al., 2012; Guindon 
et al., 2010). The best models were selected based on the corrected Akaike Information 
Criterion and were General Time Reversible (GTR)+I+G (NSP1), GTR+G (NSP2, VP4), 
Transition model (TIM2)+I (NSP3), Tamura-Nei (TrN)+G (NSP4), Hasegawa-Kishino-
Yano (HKY)+G (NSP5), TIM1+I (VP1,VP3), GTR+I (VP2), TrN+I (VP6), HKY+I+G 
(VP7). . Sub-genotypic clusters were identified as tight phylogenetic clusters with aLRT 
support greater >75%. Sequences were tested for possible recombination using the Genetic 
Algorithm Recombination Detection (GARD) algorithm implemented in Datamonkey 
(Delport et al., 2010; Kosakovsky Pond and Frost, 2005; Kosakovsky Pond et al., 2006; 
Pond and Frost, 2005). Selection analysis was performed using a combination of Single 
Likelihood Ancestor Counting (SLAC), Fixed Effects Likelihood (FEL) and Random 
Effects Likelihood (REL) analysis in Datamonkey (Kosakovsky Pond and Frost, 2005; Pond 
and Frost, 2005). Substitutions in the VP7, VP8* and VP5* regions were mapped on crystal 
structures available in PDB (www.pdb.org) using VMD 1.9.1 (Berman et al., 2000; 
Humphrey et al., 1996). For VP7 we used the RRV crystal 3FMG, for VP8* the Wa crystal 
2DWR and for VP5* the RRV crystal 2B4I was used (Aoki et al., 2009; Blanchard et al., 
2007; Yoder and Dormitzer, 2006).
2.5 Accession numbers
The nucleotide sequences for the ORFs of the eleven gene segments for each strain were 
submitted to GenBank (total of 363 sequences). The accession numbers are listed in Table 1.
3. Results
Complete ORF sequences were obtained for all 11 genes of 33 strains. Out of the 33 strains 
sequenced, 16 were G1P[8], 10 were G3P[8], and 7 were G9P[8] RVA strains.. Using RotaC 
2.0 webserver, we assigned genotypes to the 11 different gene segments for all 33 RVA 
samples. All strains were found to be Wa-like genogroup 1 strains and the consensus 11-
gene genotype constellation for the 33 RVA samples was G(1/3/9)-P[8]-I1-R1-C1-M1-A1-
N1-T1-E1-H1.
To this dataset we added 58 previously published sequences (McDonald et al., 2012) that 
were from samples collected during 2005 – 2008 from the NVSN site in Nashville (see 
supplementary material). The samples were all genogroup 1 strains with G1P[8], G3P[8] 
and G12P[8] genotypes (McDonald et al., 2012). Using the alignments of ORF sequences 
for each gene segment, we determined the optimal model based upon AICc values. We 
tested for subgenotype clustering of strains based on maximum likelihood analyses. Sub-
genotype clustering was identified by nodes with aLRT support ≥ 75%. The phylogenetic 
trees for all 11 gene segments are shown in Fig 1(A-K) and the color coding of alleles 
shown in Figure 2. The VP7 gene clusters are based on the various individual genotypes G1, 
G3, G9, G12 (Fig 1A). The G1 strains were further divided into three distinct clusters 
indicating 3 alleles [AI (red), AII (maroon), and AIII (olive)]. The strains in the AI Allele 
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clustered with the prototype G1P[8] strain Wa and the G1 genes of the two vaccines, 
RotaTeq® and Rotarix™, whereas the AII and AIII strains formed distinct, supported 
clusters.
For the other 10 gene segments the clusters were colored based on association with VP7 
genotypes (G1, G3, G9). The Wa-like G1 cluster was Allele A (red), the majority G3 cluster 
was Allele B (green), and the G9-like cluster was Allele C (blue). Strains that formed 
separate clusters outside the three designated alleles were separately clustered into Alleles D 
(purple), E (lime), F (pink), G (teal) and H (aqua). Doublets (pairs of strains) are indicated in 
gray and singleton and outgroup strains were labelled in black (Fig 1B-K, Fig 2). The 
analysis (of all 91 sequences) identified 3 to 7 subgenotypic clusters along with a few 
doublets and single outgroup strains for all 11 gene segments. Similar clustering was 
observed for most of the G3 and G9 RVA strains in all 11 gene segments (Figure 2). The G1 
strains were broadly divided into 3 alleles. Strains 2008747288, 2007719698, 2007744509, 
2007744510, except in the NSP3, VP6 and VP7 genes, clustered with the Wa like strains 
whereas strains 2008747100 and 2008747106 differed in their clustering pattern in the VP6, 
NSP3 and NSP1 genes only. The other G1 strains from this study did not exhibit a fixed 
clustering pattern across the 11 gene segments suggesting possible past intra-genotype 
reassortment events between the alleles.
Out of the 33 strains, 8 were from children known to have received at least one dose of 
RotaTeq® vaccine and these strains were referred to as vaccine failure (VF) strains. Six VF 
strains were from Rochester (G9P[8]) and one each (G3P[8]) from Nashville and Cincinnati. 
Four more G3P[8] VF strains from the McDonald et al. dataset were also included in this 
analysis. The G9 VF strains showed clustering across all 11 gene segments into Allele C 
whereas the G3 VF strains clustered primarily with Allele B, with a few exceptions (Fig 2). 
For strain 2009726997, the NSP4 gene did not cluster with other G3P[8] strains whereas 
strain VU08-09-22 clustered with Allele C for VP6, NSP1 and NSP4 genes and, for the 
NSP3 gene, strains not assigned to alleles (Fig 2).
We further tested for positive selection in the ORFs of all strains based on combined SLAC, 
FEL and REL tests. The number of codons analyzed per ORF is shown in Table 2. No 
positively selected sites were identified with high confidence (p ≤ 0.1) among the 91 RVA 
samples (Table 2). All the genes were found to contain sites under strong purifying 
selection, however, ranging from 38 of 175 sites in NSP4 (21.7%) to 187 of 326 sites 
(57.1%) in VP7 (Table 2). VP6 exhibited the second highest percentage of sites (49.6%) 
under purifying selection. The percentage of sites under strong purifying selection ranged 
from 25.8% (VP2) to 57.1% (VP7) in the structural proteins and 21.7% (NSP4) to 44.2% 
(NSP1) among the non-structural proteins (Table 2). Tests for recombination were also 
carried out, but recombination was not detected in any of the 11 genes based on results of 
GARD analysis.
Using alignments for the VP4 and VP7 genes, we identified amino acid substitutions in the 
antigenic regions between the wild type RVA strains and the RotaTeq® and Rotarix™ 
vaccine strains. For the VP7 protein, the VF strains in our data set were genotype G3/G9 so 
we compared them to the G3 component of RotaTeq® as no known G9 vaccine component 
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was available. The conservative or non-conservative nature of substitutions was based on the 
classification proposed by Zhang et al (Zhang, 2000). In the G3 VF strains, a single 
substitution at position 242 was detected (T242N) that was also present in the G9 VF strains 
(Fig 3). In G9 VP7 VF strains, substitutions were observed at positions 94, 96, 146, 189, 
208, 238 and 242 in antigenic sites A, B, E, C, and F (Fig 3). Positions 94, 96, 189, and 238 
are known neutralization escape mutation site (Aoki et al., 2009). In the G9 VP7 protein, we 
observed a N/S94G substitution, G96T substitution, Q146S substitution, S189Q substitution, 
Q208I substitution and a N238D substitution . Most of these substitutions are conservative 
in nature except the Q208I substitution (position 208), which causes change in polarity and 
thus possibly affecting epitope structure. None of the G1 strains analyzed in this study were 
VF strains so we could not perform the substitution comparison with the G1 genes of the 
vaccine strains.
The VP4 protein, which in the study represented all P[8] strains, was divided into the VP8* 
and VP5* regions for comparison. In VP8*, positions 106, 108, 113, 120, 145, 150, and 195 
show amino acid substitutions out of which positions 113, 145 and 195 are known 
neutralization escape mutation sites (Fig 4) (Dormitzer et al., 2004; Kobayashi et al., 1990; 
McKinney et al., 2007; Monnier et al., 2006; Zhou et al., 1994). In the VP8* region, we 
observed V106I substitution, I108V substitution, N113D substitution, T/M120N 
substitution, S145G substitution, E150D substitution, and N/D195G substitution in in all the 
G3 and G9 strains, and some G1 strains. The G1 strains that possessed the above 
substitutions were the ones that did not cluster with Allele A strains for most of the 11 
genes. Most of these changes are conservative in nature except a N113D substitution at 
position 113 involving a change in charge, M120N at position 120 involving a change in 
polarity and D195G substitution at position 195 involving a change in charge. Three sites, 
positions 281, 385 and 604, were observed to have substitutions in the VP5* region (Fig 5). 
The substitutions were V281I, H/Y385D and L604V respectively. Out of these three 
substitutions only H/Y385D substitution at position 385 was non-conservative with a change 
in charge and this position is also a known neutralization escape mutation site (Dormitzer et 
al., 2004; Kobayashi et al., 1990; Larralde et al., 1991; Matsui et al., 1989). These 
substitutions were also present in all G3 strains and a few G1 strains in this study suggesting 
possible vaccine failure phenotypes.
The 12 VF strains in this study shared a common clustering pattern across all 10 (except 
VP7) genes. The G9P[8] VF strains always clustered with Allele C strains whereas the 
G3P[8] VF strains primarily clustered with Allele B strains. The 11 gene segments of 4 
RVA samples from Fort Worth (2008747329, 2008747332, 2008747336, 2008747337) also 
shared similar clustering with respect to the G3P[8] VF strains (Fig 2). Vaccination histories 
were not available for those 4 samples but two of the 4 children were known to be age-
eligible for vaccination. The substitutions in the VP7 proteins of the G9P[8] VF strains were 
unique at 6 of 7 sites when compared with the G3P[8] VF strains and the vaccine strains. 
Only 1 of 7 substitutions was shared by both the G9 and G3 VF strains. All of the ten 
substitutions found in the VP4 protein were shared by both G9P[8] and G3P[8] vaccine 
failure strains. These substitutions were also present, however, in all of the other G3 and G9 
strains analyzed in this study and ~73% of the G1 strains.
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4. Discussion
In this study we sequenced 33 RVA samples collected post vaccine introduction 
(2006-2009) from sites across the continental United States. The G1 samples collected were 
evenly distributed across the 2006 – 2007 and the 2007 – 2008 seasons (none in the 2008 – 
2009 season). The majority of the G3 strains were from the 2007 – 2008 season whereas 
most G9 strains were from the 2008 – 2009 season. Maximum likelihood based 
phylogenetic clustering identified 3 to 7 distinct allelic clusters across all 11 gene segments. 
Allelic clusters for most part were defined by the VP7 gene with a few exceptions in some 
strains. Most G3 and G9 strains formed their own clusters across all 11 genes that also 
included the G1 alleles AI and AII in most cases. We hypothesize that the G1 strains from 
this study cluster on the tree with known G3 and G9 strains due to inter-allelic reassortment 
events as reported previously by McDonald et al. (McDonald et al., 2012). Such 
reassortment events may lead to constellations that are more favorable to the virus evolution. 
From the McDonald et al. dataset, which contain a large number of samples from the pre 
vaccination era (2005 – 2006), we identified 3 G1 alleles circulating in the population. The 
presence of such mixed allelic G1 reassortants pre vaccine introduction and their rise in 
numbers post vaccination may suggest that these mixed alleles are possibly selected for 
under vaccine pressure over older Wa like G1 alleles and can evolve to give rise to potential 
VF strains (Arista et al., 2006). Arista et al. suggested that the older Wa like lineages 
became extinct due to immune pressure but this study detected strains circulating in US 
(Allele AI) which are similar to older Wa-like strains. These strains may provide a reservoir 
for selection of constellations that may lead to formation of vaccine failure strains. A larger 
dataset both pre and post vaccination is required to understand the evolution of these mixed 
allelic G1 reassortants during the pre-vaccine era and their rise in numbers during the post-
vaccine era. In this study our allelic calls do not always match with previously reported 
studies (McDonald et al 2012). This is primarily due to Likelihood based measures that are 
heavily dependent on the dataset and the models used and hence these strains need to be re-
defined based on the current phylogenetic trees.
In this study, we found that the vaccine failure strains have a fixed constellation across the 
11 genes. It is possible that these constellations are present due to preferred interactions 
between proteins coded by these alleles which help in evading vaccination-induced 
protection in children (McDonald et al., 2009). All the vaccine failure strains also shared one 
substitution in VP7 gene and 10 substitutions in VP4 gene, which may lead to potential 
evasion of vaccine induced immunity. Although such fixed constellations and substitutions 
were observed in other G3 and G9 samples (e.g., G3P[8] strains from Fort Worth), we did 
not have the vaccination histories to determine whether these strains were also potential VF 
strains and we know that at least some of the children were too old to have been vaccinated 
(i.e., born more than 6 months before RotaTeq® vaccine was licensed in the US).
VP4 is an outer capsid component and in this study we found that 42.8% of the amino acid 
residues in this protein are under strong purifying selection. A previous study found the 
VP8* region of the P[8] protein associated with genotype G12 contains 103 amino acids 
under strong purifying selection (Mijatovic-Rustempasic et al., 2014). The VP4 contains 
epitopes involved in antibody-mediated neutralization (Dormitzer et al., 2004; Kobayashi et 
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al., 1990; Matsui et al., 1989) as well as functional domains involved in virus attachment 
and entry into host cells (Estes and Kapikian, 2007). It is likely that multiple selective 
pressures are influencing the evolution of VP4. VP6 also appears to be under strong 
purifying selection but the processes involved in the evolution of this protein remain to be 
determined. Previous studies have reported positive selection in the NSP2, NSP4, and VP7 
genes (Donker and Kirkwood, 2012; Mijatovic-Rustempasic et al., 2014; Song and Hao, 
2009) but in this study we did not find evidence of this process in our data sets for these 3 
genes
The VP7 and VP4 proteins form the outer surface structure of the viral capsid, hence their 
antigenic regions have been well characterized. RVA immunity is known to be both 
homotypic, heterotypic and polygenic (Desselberger and Huppertz, 2011). To identify sites 
that could possibly help escape vaccine derived immunity, we looked at the alignments of 
the antigenic regions of the RVA strains in this study. For the VP7 gene, seven substitutions 
were observed in all G9 strains out of which four were at known neutralization escape sites 
(Hoshino et al., 2005; Hoshino et al., 2004). When compared with Rotarix™ and RotaTeq® 
only one change Q208I was accompanied by a change in polarity observed in the G9 strains. 
Change in polarity at this site may possibly help the G9 strains escape neutralization 
although we did not find similar substitution in the G3 vaccine failure strain. Zeller et al. 
(Zeller et al., 2012) described a N238D change in G3P[8] strains from Belgium that creates 
a potential N-linked glycosylation site that is absent in the G3 strain of RotaTeq®. All 
strains in this study, except the G9 strains, have an N at position 238 indicating the presence 
of this predicted glycosylation site. For the G9 strains, a D at position 238 gives rise to a 
predicted integrin binding site instead of a glycosylation site. Whereas the glycosylation site 
is thought to facilitate viral growth in cell culture systems, the function of the integrin 
binding site is unknown (Graham et al., 2005). The N238D mutation, however, appears in 
virulent murine RVA strains produced by serial passage of avirulent RVA strains in mice 
(Tsugawa et al., 2014). It is interesting to note that even the Rotarix™ VP7 protein contains 
the same glycosylation site at position. Most of the changes at the VP7 neutralization escape 
sites identified in this study were conservative in nature. The mutations in the G9 strains 
were unique to the group but the mutation present in G3 strains were present in all G3 and 
even some G1 strains in this study. In the VP8* region of the VP4 gene, 7 substitutions were 
observed out of which 4 were non conservative in nature when compared with the Rotarix™ 
and the RotaTeq® consensus sequences. Other conserved epitope changes at multiple sites 
have previously been reported recently in strains circulating in the US and Belgium 
(Mijatovic-Rustempasic et al., 2014; Zeller et al., 2012). The functional relevance of these 
changes at known epitopes is yet to be determined. With regard to the non-conservative 
amino acid substitutions in the VP8* region, the N113D substitution at position 113 and 
D195G substitution at position 195 involve a change in charge, from neutral to negative and 
negative to neutral, respectively. Both of these sites lie in known neutralization escape sites 
and differ from the sequences of Rotarix™ and RotaTeq®. The other non-conservative 
change was at position 120 where an M120N change was accompanied with change in 
polarity. In the VP5* region there were three positions were substitutions were observed. 
Out of the 3, H/Y385D substitution at position 385, a neutralization escape site, was non-
conservative with a change in charge. Amino acid residues 382 – 400 in the VP5* region 
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also contain a potential membrane interaction loop and may be essential for viral virulence, 
especially in facilitating viral attachment or penetration (Dormitzer et al., 2004; Trask et al., 
2010), In a cell culture-murine model system, a charge change at this position has been 
shown to be associated with reversion of an avirulent strain to a virulent one (Tsugawa et al., 
2014). It is interesting to note that these substitutions are present in all sequences except the 
Allele A strains. If these substitutions are responsible for neutralization escape, it would 
suggest that the Allele A strains would gradually be replaced over time by the other 
reassortant G1 types due to vaccine derived evolutionary pressures. A more detailed analysis 
with multiple strains from pre vaccination years is necessary to assess whether these 
substitutions are actively arising under vaccine pressure.
The main limitation of the genetic analysis performed in this study was the closely related 
nature of the strains that were sampled. All strains shared a common Wa like genogroup 1 
backbone with the only difference being in the VP7 gene (G1/G3/G9). The low genetic 
distance between the genes of the strains sampled may interfere in understanding better the 
effect of vaccine pressure, geographical distance, and time on the evolution of these virus 
strains currently circulating in continental US. A more detailed sampling of multiple 
genotypes with different backbones is currently underway to determine better the effect of 
vaccine pressures on circulating strains. Also to test the hypothesis that specific amino acid 
substitutions can lead to immune evasion of vaccine induced immunity, VF strains should be 
compared to strains from unvaccinated children that are matched by age, site, and date of 
illness to control for these variables. Such studies are currently underway at CDC.
5. Conclusion
Large scale full genome sequencing initiatives are necessary to understand the changes in 
circulating strains post introduction of the vaccine. We were able to capture changes in 
recent circulating strains that could possibly lead to the rise of vaccine failure strains. We 
were also able to identify inter-allelic reassortment events in currently circulating G1 strains. 
Such reassortment events have been reported previously, albeit infrequently, (McDonald et 
al., 2011; McDonald et al., 2012) and can help in producing possibly strains better suited to 
escape vaccine derived immune pressure. This study highlights the need for further 
surveillance and other full genome initiatives to study in detail the evolution of RVA strains 
currently in circulation.
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Figure 1. 
Maximum likelihood trees with aLRT values showing branch support for the 11 RVA genes. 
The different alleles are colored in red, green, blue, purple, lime, pink, teal and aqua for 
Alleles A, B, C, D, E, F, G and H respectively. Doublets and singletons are shown in grey 
and black, respectively (Fig. 1A) VP7. The Allele A in further divided into three clusters: 
red strains that mostly cluster with G1 (Wa) strains and maroon and olive strains that forms 
a distinct clusters from the reference Wa Strain. (1B) VP4; (1C) VP6; (1D) VP1; (1E) VP2; 
(1F) VP3; (1G) NSP1; (1H) NSP2; (1I) NSP3; (1J) NSP4; (1K) NSP5. To see the individual 
strains comprising each colored triangle, consult the supplemental figures (see 
supplementary material).
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Figure 2. 
Allelic clusters for the 91 RVA strains. Genes from strains that clustered with Allele A (G1) 
are shown in red, maroon and olive. Allele B (G3) genes are shown in green and Allele C 
(G9) strains are shown in blue, Independent clusters are shown in purple (Allele D), lime 
(Allele E), pink (Allele F), teal (Allele G) and aqua (Allele H). Doublet strains are shown in 
grey and singleton strains in black.
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Figure 3. 
Crystal structure of RVA VP7 protein (3FMG). Substitutions at the antigenic site are 
marked in green and substitutions at reported neutralization escape mutation sites are 
marked in red.
Roy et al. Page 28
Infect Genet Evol. Author manuscript; available in PMC 2015 October 26.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 4. 
Crystal structure of RVA VP8* region (2DWR). Substitutions at the antigenic site are 
marked in green and substitutions at reported neutralization escape mutation sites are 
marked in red.
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Figure 5. 
Crystal structure of RVA VP5* region (2B4I). Substitutions at the antigenic site are marked 
in green and substitutions at reported neutralization escape mutation sites are marked in red.
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